Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18667208 | 0.90 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL18667866 | 0.90 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL16299891 | 0.89 | LMNA (0.58) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL3701581 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL20782480 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL19390721 | 0.87 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL12473650 | 0.86 | HTT (0.54) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL12473649 | 0.86 | HTT (0.54) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL14146574 | 0.86 | SLC1A3 (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL734427 | 0.86 | LMNA (0.61) | LMNASMN1; SMN2SLC1A3SLC1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| WO-2017048950-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2017007694-A1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885SMN1; SMN2 4716/4885SLC1A3 3599/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885SMN1; SMN2 4716/4885SLC1A3 3599/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885SMN1; SMN2 4716/4885SLC1A3 3599/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | LMNA 3781/4885SMN1; SMN2 4716/4885SLC1A3 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.